Across TCGA pan-cancer cohorts, OSBP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OSBP2 data layer compared with 18 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher OSBP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OSBP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and PRAD are the cancer types where OSBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
UCEC	OS	Median	II,III,IV	0.937	0.457	.022	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.140	0.780	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OSBP2 tumor-vs-normal RNA expression · all OSBP2 data types